
Histopathology reports in melanoma patients can predict immune-related adverse events during checkpoint inhibitor treatment.


coremsg

Melanoma histopathology predicted which patients were most likely to develop immune-related adverse events while taking checkpoint inhibitors.

ICIs in Melanoma: Predicting Immune-related Adverse Events


Predicting Immune-related Adverse Events in Melanoma Patients Using Histopathology Reports
